Dr. Len Schleifer, CEO of Regeneron: Betting on Science and Saving a President
Dr. Leonard Schleifer, founder, President & CEO of Regeneron, joins inSpired to share how a young neurologist built one of the largest companies in the S&P 500 still run by its founders. His mentor had called the idea the stupidest he’d ever heard. Nearly four decades later, Schleifer and Dr. George Yancopoulos are still in the same roles, and Regeneron has more than 50 programs in the clinic and about $18 billion in the bank.
In this episode:
How Regeneron started in 1988 with $1 million and a plan to regenerate neurons, and how Schleifer recruited Dr. George Yancopoulos
Why Regeneron refused to bet the company on a single molecule through 25 straight years of losses
The EYLEA approval and a first year of $800 million in sales
The inside story of treating President Trump with Regeneron’s COVID antibody cocktail
Dupixent’s growth across nine indications, and the next generation of type 2 immunology, including an effort to cure allergy
The pipeline Schleifer says gets no credit: an obesity drug that also lowers cholesterol, Lynozyfic in multiple myeloma, Factor XI anticoagulants, and the C5 franchise
The Regeneron Genetics Center, AI in drug discovery, and a gene therapy that lets children born with profound deafness hear, given away for free
Regeneron’s approach to M&A, succession, and Schleifer’s advice for the next founder
“If you’re running a business, you don’t want to be a fan of your molecules.”
“We’re not renters, we’re owners.”
Chapters
0:00 Cold open
1:49 Founding Regeneron in 1988
8:04 Working with Dr. George Yancopoulos
11:44 Top moments and the EYLEA approval
15:05 Treating President Trump for COVID
19:22 EYLEA and EYLEA HD today
20:18 Dupixent and the type 2 franchise
23:20 Next generation immunology
29:39 Obesity: a GLP that lowers cholesterol
33:42 Lynozyfic in multiple myeloma
34:50 Factor XI anticoagulation
39:46 The C5 franchise
42:48 The Regeneron Genetics Center
48:06 Curing genetic deafness
50:03 AI in drug discovery
52:17 M&A philosophy
55:47 Succession and advice for the next Len
Read the full transcript: Download the PDF
inSpired is for investors, by an investor: conversations with executives building tomorrow’s great companies.